BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol 2019;10:2847. [PMID: 31849996 DOI: 10.3389/fimmu.2019.02847] [Cited by in Crossref: 52] [Cited by in F6Publishing: 78] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Tang J, Liu C, Liu S, Zhou X, Lu J, Li M, Zhu L. Inhibition of JAK1/STAT3 pathway by 2-methoxyestradiol ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like mouse model. Eur J Pharmacol 2022;933:175276. [PMID: 36130639 DOI: 10.1016/j.ejphar.2022.175276] [Reference Citation Analysis]
2 Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022;36:1409-31. [PMID: 35980214 DOI: 10.1111/jdv.18345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhang W, Li X, Chen B, Zhang J, Torres-culala KMT, Zhou C. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study. Front Med 2022;9:891434. [DOI: 10.3389/fmed.2022.891434] [Reference Citation Analysis]
4 Zhou Y, Wang P, Chen XY, Yan BX, Landeck L, Wang ZY, Xu F, Zheng M, Man XY. Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes. Cell Prolif 2022;:e13290. [PMID: 35716036 DOI: 10.1111/cpr.13290] [Reference Citation Analysis]
5 Hou Z, Su X, Han G, Xue R, Chen Y, Chen Y, Wang H, Yang B, Liang Y, Ji S. JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis. Front Med 2022;9:859330. [DOI: 10.3389/fmed.2022.859330] [Reference Citation Analysis]
6 Cheng J, Facheris P, Ungar B, Guttman-Yassky E. Current emerging and investigational drugs for the treatment of chronic hand eczema. Expert Opin Investig Drugs 2022. [PMID: 35658708 DOI: 10.1080/13543784.2022.2087059] [Reference Citation Analysis]
7 Duraisamy P, Jagadeesan S, Thomas J. Tofacitinib in the treatment of refractory eczemas - a case series. J Dermatolog Treat 2022;:1-3. [PMID: 35642323 DOI: 10.1080/09546634.2022.2082355] [Reference Citation Analysis]
8 Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol 2022. [PMID: 35606650 DOI: 10.1007/s40257-022-00699-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Narla S, Silverberg JI. The suitability of treating atopic dermatitis with Janus kinase inhibitors. Expert Rev Clin Immunol 2022. [PMID: 35377276 DOI: 10.1080/1744666X.2022.2060822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tan S, Phan P, Law JY, Choi E, Chandran NS. Qualitative analysis of topical corticosteroid concerns, topical steroid addiction and withdrawal in dermatological patients. BMJ Open 2022;12:e060867. [PMID: 35296492 DOI: 10.1136/bmjopen-2022-060867] [Reference Citation Analysis]
11 Zhang J, Qi F, Dong J, Tan Y, Gao L, Liu F. Application of Baricitinib in Dermatology. JIR 2022;Volume 15:1935-41. [DOI: 10.2147/jir.s356316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mikhaylov D, Glickman JW, Del Duca E, Nia J, Hashim P, Singer GK, Posligua AL, Florek AG, Ibler E, Hagstrom EL, Estrada Y, Rangel SM, Colavincenzo M, Paller AS, Guttman-Yassky E. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res 2022. [PMID: 35230488 DOI: 10.1007/s00403-022-02336-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol 2022. [PMID: 35209781 DOI: 10.1080/1744666X.2022.2047022] [Reference Citation Analysis]
14 Bochicchio MT, Di Battista V, Poggio P, Carrà G, Morotti A, Brancaccio M, Lucchesi A. Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms. Cancers (Basel) 2022;14:972. [PMID: 35205715 DOI: 10.3390/cancers14040972] [Reference Citation Analysis]
15 Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata - Aktuelles Verständnis und Management. J Dtsch Dermatol Ges 2022;20:59-93. [PMID: 35040563 DOI: 10.1111/ddg.14689_g] [Reference Citation Analysis]
16 Labib A, Yosipovitch G. Itchy Toxicodendron Plant Dermatitis. Allergies 2022;2:16-22. [DOI: 10.3390/allergies2010002] [Reference Citation Analysis]
17 Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata - Current understanding and management. J Dtsch Dermatol Ges 2022;20:59-90. [PMID: 35040577 DOI: 10.1111/ddg.14689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chang WL, Lee WR, Kuo YC, Huang YH. Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention. Front Cell Dev Biol 2021;9:797026. [PMID: 34970551 DOI: 10.3389/fcell.2021.797026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Arora H, Boothby-Shoemaker W, Braunberger T, Lim HW, Veenstra J. Safety of conventional immunosuppressive therapies for patients with dermatological conditions and coronavirus disease 2019: A review of current evidence. J Dermatol 2021. [PMID: 34962304 DOI: 10.1111/1346-8138.16182] [Reference Citation Analysis]
20 Di Filippo P, Russo D, Attanasi M, Di Pillo S, Chiarelli F. Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children. Biomedicines 2021;9:1615. [PMID: 34829844 DOI: 10.3390/biomedicines9111615] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Kordbacheh F, Farah CS. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5471. [PMID: 34771633 DOI: 10.3390/cancers13215471] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Vičić M, Kaštelan M, Brajac I, Sotošek V, Massari LP. Current Concepts of Psoriasis Immunopathogenesis. Int J Mol Sci 2021;22:11574. [PMID: 34769005 DOI: 10.3390/ijms222111574] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
23 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2-Inhibition: Potenzial bei der Behandlung chronisch-entzündlicher Immunerkrankungen. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34661350 DOI: 10.1111/ddg.14585_g] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Luo Y, Alexander M, Gadina M, O'Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin Immunol 2021;148:911-25. [PMID: 34625141 DOI: 10.1016/j.jaci.2021.08.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
25 Ravipati A, Nolan S, Alphonse M, Dikeman D, Youn C, Wang Y, Orlando N, Patrick G, Lee S, Ortines RV, Liu H, Miller RJ, Dillen CA, Marchitto M, Cai SS, Miller LS, Archer NK. IL-6R/Signal Transducer and Activator of Transcription 3 Signaling in Keratinocytes rather than in T Cells Induces Psoriasis-Like Dermatitis in Mice. J Invest Dermatol 2021:S0022-202X(21)02291-0. [PMID: 34626614 DOI: 10.1016/j.jid.2021.09.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Carrasco I, Ferrer L, Puigdemont A. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. J Feline Med Surg 2021;:1098612X211048458. [PMID: 34612749 DOI: 10.1177/1098612X211048458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34580985 DOI: 10.1111/ddg.14585] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Braegelmann C, Niebel D, Ferring-Schmitt S, Fetter T, Landsberg J, Hölzel M, Effern M, Glodde N, Steinbuch S, Bieber T, Wenzel J. Epigallocatechin-3-gallate exhibits anti-inflammatory effects in a human interface dermatitis model-implications for therapy. J Eur Acad Dermatol Venereol 2021. [PMID: 34585800 DOI: 10.1111/jdv.17710] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Salvati L, Cosmi L, Annunziato F. From Emollients to Biologicals: Targeting Atopic Dermatitis. Int J Mol Sci 2021;22:10381. [PMID: 34638722 DOI: 10.3390/ijms221910381] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Słuczanowska-Głąbowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med 2021;10:4307. [PMID: 34640327 DOI: 10.3390/jcm10194307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Le M, Berman-Rosa M, Ghazawi FM, Bourcier M, Fiorillo L, Gooderham M, Guenther L, Hanna S, Hong HC, Landells I, Lansang P, Marcoux D, Wiseman MC, Yeung J, Lynde C, Litvinov IV. Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Front Med (Lausanne) 2021;8:682547. [PMID: 34540860 DOI: 10.3389/fmed.2021.682547] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Barbieux C, Bonnet des Claustres M, Fahrner M, Petrova E, Tsoi LC, Gouin O, Leturcq F, Nicaise-Roland P, Bole C, Béziat V, Bourrat E, Schilling O, Gudjonsson JE, Hovnanian A. Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses. J Allergy Clin Immunol 2021:S0091-6749(21)01398-1. [PMID: 34543653 DOI: 10.1016/j.jaci.2021.08.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
33 Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, Geissler K, McInnes IB, Takeuchi T, Trauner M, Winthrop K, de Wit M, Boehncke WH, Falzon L, van der Heijde D. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open 2020;6:e001374. [PMID: 33188136 DOI: 10.1136/rmdopen-2020-001374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
34 Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol 2021. [PMID: 34403083 DOI: 10.1007/s12016-021-08883-0] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
35 Yang X, Kambe N, Takimoto-ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacology & Therapeutics 2021;224:107830. [DOI: 10.1016/j.pharmthera.2021.107830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kang SY, Um JY, Chung BY, Kim JC, Park CW, Kim HO. Differential Diagnosis and Treatment of Itching in Children and Adolescents. Biomedicines 2021;9:919. [PMID: 34440123 DOI: 10.3390/biomedicines9080919] [Reference Citation Analysis]
37 Zhou X, Guan Z, Jin X, Zhao J, Chen G, Ding J, Ren Y, Zhai X, Zhou Q, Guan Z. Reversal of alopecia areata, osteoporosis follow treatment with activation of Tgr5 in mice. Biosci Rep 2021;41:BSR20210609. [PMID: 34196345 DOI: 10.1042/BSR20210609] [Reference Citation Analysis]
38 Tseng JC, Chang YC, Huang CM, Hsu LC, Chuang TH. Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis. Pharmaceutics 2021;13:1064. [PMID: 34371756 DOI: 10.3390/pharmaceutics13071064] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part I. A comprehensive review. J Am Acad Dermatol 2021:S0190-9622(21)02071-5. [PMID: 34246698 DOI: 10.1016/j.jaad.2021.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
40 Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, McGee R, Yeleswaram S. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol 2021;22:555-66. [PMID: 33982267 DOI: 10.1007/s40257-021-00610-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
41 Dillon KL. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol 2021;14:691-714. [PMID: 34211288 DOI: 10.2147/CCID.S309215] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
42 Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K. Lichen planus - ein Klinikleitfaden. J Dtsch Dermatol Ges 2021;19:864-83. [PMID: 34139075 DOI: 10.1111/ddg.14565_g] [Reference Citation Analysis]
43 Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K. Lichen planus - a clinical guide. J Dtsch Dermatol Ges 2021;19:864-82. [PMID: 34096678 DOI: 10.1111/ddg.14565] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
44 Maksimow A, Stintzing D, Wohlrab J. [Alopecia areata with good response to tofacitinib]. Hautarzt 2021;72:525-7. [PMID: 33044559 DOI: 10.1007/s00105-020-04704-1] [Reference Citation Analysis]
45 Wongvibulsin S, Sutaria N, Kannan S, Alphonse MP, Belzberg M, Williams KA, Brown ID, Choi J, Roh YS, Pritchard T, Khanna R, Eseonu AC, Jedrych J, Dillen C, Kwatra MM, Chien AL, Archer N, Garza LA, Dong X, Kang S, Kwatra SG. Transcriptomic analysis of atopic dermatitis in African Americans is characterized by Th2/Th17-centered cutaneous immune activation. Sci Rep 2021;11:11175. [PMID: 34045476 DOI: 10.1038/s41598-021-90105-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, Mostaghimi A, Silverberg JI, Schneeweiss S. Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol 2021;157:805-16. [PMID: 34037662 DOI: 10.1001/jamadermatol.2021.1570] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
47 Sherman S, Tzur Bitan D, Leshem YA, Hodak E. Reply to: Comments on "Hidradenitis suppurativa and atopic dermatitis: A two-way association". J Am Acad Dermatol 2021:S0190-9622(21)01004-5. [PMID: 34044104 DOI: 10.1016/j.jaad.2021.05.019] [Reference Citation Analysis]
48 Yin Y, Liu M, Zhou E, Chang X, He M, Wang M, Wu J. Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2021. [PMID: 33990888 DOI: 10.1007/s10067-021-05686-8] [Reference Citation Analysis]
49 Legat FJ. Itch in Atopic Dermatitis - What Is New? Front Med (Lausanne) 2021;8:644760. [PMID: 34026782 DOI: 10.3389/fmed.2021.644760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y, Lyu X. JAK-inhibitors for dermatomyositis: A concise literature review. Dermatol Ther 2021;34:e14939. [PMID: 33713527 DOI: 10.1111/dth.14939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
51 Solimani F, Meier K, Ghoreschi K. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. Eur J Immunol 2021;51:1071-5. [PMID: 33675065 DOI: 10.1002/eji.202149173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
52 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Miyagaki T, Okano T, Nakajima K, Mitsuishi S, Kishi A, Miyano K, Takeuchi S, Kadono T. A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment. Dermatol Ther 2021;34:e14888. [PMID: 33605031 DOI: 10.1111/dth.14888] [Reference Citation Analysis]
54 Dincer Rota D, Emeksiz MAC, Erdogan FG, Yildirim D. Experience with oral tofacitinib in severe alopecia areata with different clinical responses. J Cosmet Dermatol 2021;20:3026-33. [PMID: 33533091 DOI: 10.1111/jocd.13966] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
55 Liang J, Cao H, Yang Y, Ke Y, Yu Y, Sun C, Yue L, Lin J. Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Front Med (Lausanne) 2021;8:626953. [PMID: 33614683 DOI: 10.3389/fmed.2021.626953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
56 Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021;397:754-66. [PMID: 33515492 DOI: 10.1016/S0140-6736(21)00184-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
57 Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag 2020;16:1319-32. [PMID: 33408476 DOI: 10.2147/TCRM.S292504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Honma M, Hayashi K. Psoriasis: Recent progress in molecular‐targeted therapies. J Dermatol 2021;48:761-77. [DOI: 10.1111/1346-8138.15727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
59 Meier K, Schloegl A, Poddubnyy D, Ghoreschi K. Skin manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 2020;12:1759720X20975915. [PMID: 33343725 DOI: 10.1177/1759720X20975915] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
60 Dijkgraaf FE, Toebes M, Hoogenboezem M, Mertz M, Vredevoogd DW, Matos TR, Teunissen MBM, Luiten RM, Schumacher TN. Labeling and tracking of immune cells in ex vivo human skin. Nat Protoc 2021;16:791-811. [PMID: 33349704 DOI: 10.1038/s41596-020-00435-8] [Reference Citation Analysis]
61 Seok SH, Kim DH. Pathogenesis of vitiligo. J Korean Med Assoc 2020;63:725-30. [DOI: 10.5124/jkma.2020.63.12.725] [Reference Citation Analysis]
62 Vu YH, Hashimoto-Hachiya A, Takemura M, Yumine A, Mitamura Y, Nakahara T, Furue M, Tsuji G. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis. Int J Mol Sci 2020;21:E9412. [PMID: 33321923 DOI: 10.3390/ijms21249412] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
63 Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther 2021;34:e14563. [PMID: 33210790 DOI: 10.1111/dth.14563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M, Frouin E, Azzopardi N, Chevrier J, Serres L, Godet J, Levillain P, Paintaud G, Ferru A, Rouleau L, Delwail A, Silvain C, Tasu JP, Morel F, Ragot S, Lecron JC. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). Oncoimmunology 2020;9:1848058. [PMID: 33299659 DOI: 10.1080/2162402X.2020.1848058] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Humrich JY, Bernardes JP, Ludwig RJ, Klatzmann D, Scheffold A. Phenotyping of Adaptive Immune Responses in Inflammatory Diseases. Front Immunol 2020;11:604464. [PMID: 33324421 DOI: 10.3389/fimmu.2020.604464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
66 Wu J, Del Duca E, Espino M, Gontzes A, Cueto I, Zhang N, Estrada YD, Pavel AB, Krueger JG, Guttman-Yassky E. RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing. Front Immunol 2020;11:597741. [PMID: 33329590 DOI: 10.3389/fimmu.2020.597741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
67 Pietschke K, Holstein J, Meier K, Schäfer I, Müller-Hermelink E, Gonzalez-Menendez I, Quintanilla-Martinez L, Ghoreschi FC, Solimani F, Ghoreschi K. The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition. Exp Dermatol 2021;30:262-70. [PMID: 33113249 DOI: 10.1111/exd.14226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
68 Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Immunotargets Ther 2020;9:255-72. [PMID: 33204661 DOI: 10.2147/ITT.S229667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
69 Komiya E, Tominaga M, Kamata Y, Suga Y, Takamori K. Molecular and Cellular Mechanisms of Itch in Psoriasis. Int J Mol Sci 2020;21:E8406. [PMID: 33182442 DOI: 10.3390/ijms21218406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
70 Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021;80:71-87. [PMID: 33158881 DOI: 10.1136/annrheumdis-2020-218398] [Cited by in Crossref: 24] [Cited by in F6Publishing: 58] [Article Influence: 12.0] [Reference Citation Analysis]
71 Al Khalili A, Dutz JP. Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE? Curr Treat Options in Rheum 2020;6:406-17. [DOI: 10.1007/s40674-020-00155-w] [Reference Citation Analysis]
72 Tokuyama M, Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci 2020;21:E7488. [PMID: 33050592 DOI: 10.3390/ijms21207488] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
73 Pastor-Fernández G, Mariblanca IR, Navarro MN. Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities. Cells 2020;9:E2044. [PMID: 32906785 DOI: 10.3390/cells9092044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
74 Gerstenberger BS, Ambler C, Arnold EP, Banker ME, Brown MF, Clark JD, Dermenci A, Dowty ME, Fensome A, Fish S, Hayward MM, Hegen M, Hollingshead BD, Knafels JD, Lin DW, Lin TH, Owen DR, Saiah E, Sharma R, Vajdos FF, Xing L, Yang X, Yang X, Wright SW. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem 2020;63:13561-77. [PMID: 32787094 DOI: 10.1021/acs.jmedchem.0c00948] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
75 Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K. COVID‐19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen. J Dtsch Dermatol Ges 2020;18:795-809. [PMID: 32881300 DOI: 10.1111/ddg.14169_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
76 Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K. COVID-19 and immunological regulations - from basic and translational aspects to clinical implications. J Dtsch Dermatol Ges 2020;18:795-807. [PMID: 32761894 DOI: 10.1111/ddg.14169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
77 Katoh N. Emerging treatments for atopic dermatitis. J Dermatol 2021;48:152-7. [PMID: 32677122 DOI: 10.1111/1346-8138.15504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
78 Fetter T, Wenzel J. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies. Exp Dermatol 2020;29:1123-32. [PMID: 32633821 DOI: 10.1111/exd.14146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
79 D'Urso DF, Chiricozzi A, Pirro F, Calabrese L, Caldarola G, Fossati B, De Simone C, Peris K. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol 2020;155:411-20. [PMID: 32545945 DOI: 10.23736/S0392-0488.20.06658-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]